key: cord-0712980-35q3188d
authors: Faust, Lena; Zimmer, Alexandra J.; Kohli, Mikashmi; Saha, Senjuti; Boffa, Jody; Bayot, Marlon L.; Nsofor, Ifeanyi; Campos, Leonel; Mashamba-Thompson, Tivani; Herrera, Rosa; Emeka, Elom; Shrestha, Suvesh; Ugarte-Gil, Cesar; Katamba, Achilles; Pambudi, Imran; Bichara, David; Calderon, Roger I.; Ahmadzada, Namatullah; Safdar, Muhammad Aamir; Nikam, Chaitali; Lázari, Carolina dos Santos; Hussain, Hamidah; Win, Myint Myint; Than, Kyaw Zin; Ahumibe, Anthony; Waning, Brenda; Pai, Madhukar
title: SARS-CoV-2 testing in low- and middle-income countries: availability and affordability in the private health sector
date: 2020-10-14
journal: Microbes Infect
DOI: 10.1016/j.micinf.2020.10.005
sha: b0ea27057c890a6b5a2c1f5ab8ca5783015d93ad
doc_id: 712980
cord_uid: 35q3188d

nan

SARS-CoV-2 testing is a major bottleneck globally, especially in low-and middle-income countries (LMICs). As the public health sector struggles to meet the increasing need for tests, there is a potential role for the private health sector to expand SARS-CoV-2 testing capacity. [1, 2] We aimed to investigate the availability and affordability of SARS-CoV-2 testing in the private health sector in these settings.

We surveyed LMICs in which a large proportion of patients seek care in the private sector, [3, 4] sending the survey via email as a protected word document to 68 contacts across 22 countries. Contact information was obtained through attendee lists at passed global health conferences or through colleagues in the respective countries. The survey questions covered in which sectors (public, private or both) COVID-19 testing (serological and PCR) were available, what type of financing scheme was in place for testing (e.g. whether testing was paid out-of-pocket by patients), and what type of reimbursement mechanism (if any) exists for testing in the private sector (e.g. if the government is reimbursing the private sector for testing costs). The survey also collected data on costs of testing in the private sector, which components of testing were included in these costs (e.g. cost of test itself, transport costs, etc), and patient eligibility criteria (if any) for reimbursement. We received 30 responses from 15 countries between May and June 2020. Respondents held varied roles in the public and private sectors, some being directly involved in COVID-19 testing. No patient data nor individual subject data were collected. Beyond the name of the country, no identifying information was collected. As the survey covers country-level policies only, this does not constitute human subjects research and did not require ethical approval.

The number of respondents per country, respondent roles, the availability and price of private sector SARS-CoV-2 PCR and serological testing, and reimbursement mechanisms are summarized in Table 1 . In 11 of the 15 countries, PCR testing (specifically real-time reverse transcription polymerase chain reaction, rRT-PCR) for SARS-CoV-2 is available in both the public and private sectors. In Myanmar, Nepal, Tanzania, and Uganda, SARS-CoV-2 PCR testing is available only in the public sector.

Various payment and reimbursement models were reported among the surveyed countries for private sector testing, including payment of the entire cost out-of-pocket by patients, reimbursement of the private sector through the government or donors, or the provision of resources (e.g. test kits) to the private sector directly from the government.

The price paid by patients for PCR testing ranged from 0 to 202 USD per test. In all countries not offering free private sector testing, respondents stated that the price includes not only the cost of the test (reagents, kits), but also sample collection and transportation costs, costs of healthcare worker personal protective equipment, and laboratory overhead and profits.

Respondents in Brazil, Mexico, Peru and South Africa reported that testing prices (ranging from 50 to 202 USD in these countries) were not capped by the government, and prices varied across the country. In countries that imposed a price cap (Bangladesh, India, and the Philippines), the price to patients ranged from 29 to 68 USD (median: 41 USD). However, respondents also highlighted that even in situations where the price of testing is capped, private facilities can charge additional costs (e.g. administrative fees). In addition, among countries offering PCR testing in the private sector, all except three countries (Afghanistan, India and the Philippines) reported that any patient able to pay can be tested in the private sector without meeting any additional criteria (e.g. symptoms).

Serological testing (i.e. rapid antibody testing) for SARS-CoV-2 is available in the private sector in only 6 of 15 countries (Brazil, Indonesia, Mexico, Pakistan, Peru, and the Philippines). Respondents in Bangladesh, India, Myanmar, Nepal, Nigeria, South Africa, and Tanzania stated that serological tests are currently being offered in neither the private nor public sector, whilst respondents from Afghanistan and Uganda stated that serological testing occurs in the public sector only. Respondents in South Africa and India however note that implementation of serological testing is currently under evaluation.

No mechanism of reimbursement through the government was available for private sector serological testing in any of the six countries. Respondents in Brazil, Indonesia, Mexico, Pakistan (at some but not all facilities), and Peru reported that the full cost of serological testing is paid out-of-pocket by patients (price range: 18 to 68 USD per test). The price of serological testing was not capped by the government in any of the six countries conducting testing in the private sector. Across all countries, respondents reported that anyone able to pay could be tested.

As LMICs are now seeing a rise in COVID-19 cases, particularly in South Asia, South America, and Africa, [5] harnessing the additional testing capacity of the private sector provides relief to resource-constrained public systems; however, a number of countries reported persisting barriers with regard to engaging and integrating the private sector into the national COVID-19 response. Such barriers included the limited number of laboratories with the appropriate biosafety level (BSL) classification and available safety cabinets for processing samples associated with SARS-CoV-2 (Pakistan, Myanmar). Moreover, as indicated by some respondents, even in private laboratories operating at the required BSL, obtaining governmental approval to conduct SARS-CoV-2 testing remains challenging. In addition, being primarily concentrated in urban centres, private sector testing may be less accessible to rural populations.

Other concerns include the high cost of testing and the challenges of cost regulation in the private sector. High demand for testing in a non-regulated market contributes to high prices in J o u r n a l P r e -p r o o f the private sector, and the high patient-borne costs reported present a major barrier to testing, especially in LMICs. Even in settings where the government has capped prices, private facilities can still charge patients additional fees that are not restricted by the cap. High costs in the private sector mean more reliance on public sector testing, limiting the ability of the private sector to reduce the burden on the public sector. Lastly, our finding that most individuals able to pay can receive a PCR or serological test in the private sector demonstrates that current private sector testing practices may not necessarily align with government priorities or policies. Important limitations of our survey include its small sample size. Firstly, responses were received from only 15 (68%) of the 22 countries contacted, and of the 15 countries for which responses were received, 9 (60%) included only one respondent. Therefore, not all countries surveyed are represented, and furthermore, our results reflect only the knowledge and expertise of specific respondents and are not necessarily representative of the overall situation in a country. This is particularly important to note given that respondents held different roles within their countries (e.g. public vs. private health sector), and their experiences and knowledge of COVID-19 testing in the private sector may therefore differ. In addition, as contacts were obtained from prior global health conference attendees and through colleagues in the respective countries, the survey does not fully represent the relevant experts in a particular country. Further, it is possible that reporting bias influenced survey responses, as respondents may report aspirational scenarios rather than what most accurately represents the current situation in their country. Lastly, given that the COVID-19 situation is continuously changing, these survey results only reflect the situation as reported by the respondent(s) at the time of the survey, and is likely to change as countries continue to work to improve testing capacity and engage the private sector.

In summary, given the large contribution of the private sector to healthcare provision in LMICs and the WHO recommendation of adopting a whole-of-society approach in responding to COVID-19, engaging the private sector in COVID-19 testing in LMICs is critical to building up surge capacity. [1, 6] Although recognizing the limitations of this small sample size, the results of our survey highlight that engagement of the private sector in SARS-CoV-2 testing is not uniform and remains weak in many countries. Governments must effectively regulate the private sector, establish mechanisms for strategic purchasing of essential services, address supply chain issues and supplier price control, and facilitate public-private partnerships. [1] Such partnerships have been able to address similar issues with high private health sector test prices for conditions such as TB and HIV [4, 7] and therefore increase affordability and access to testing. The state government pays 26 to 38 USD per test on behalf of the patient, to cover laboratory overhead and profits. Patients tested in private facilities that function as part of the public network of laboratories are tested free of cost, however, additional private laboratories that do not function as part of the public laboratory network have recently also been allowed to conduct testing, and these may charge a cost to patients (approximately 112 USD). (i)

Patients tested within the national network must meet case definition criteria and have a referral for testing. For patients tested outside of the network, no reimbursement is available. (j)

Some not-for-profit organizations provide free testing, with resources supplied by the government, and transportation and other costs borne by the organization. (k)

The government has recently capped testing costs. Information on specific cap amount unavailable. (l)

There is no reimbursement via the government, but free testing is available for some employees through private sector donors. (m)

The government reimburses the private sector via a solidarity fund (mixed government and donor reimbursement model).

Those unable to pay AND meeting the following clinical criteria are eligible for free testing: Individuals with acute respiratory symptoms meeting one of the following criteria: in the last 14 days -had direct contact with a COVID case, attended a health care centre where COVID patients are being treated, arrived from outside the country, or have been admitted to hospital with pneumonia of unknown etiology. For other patients seeking to be tested, extent of coverage is dependent on availability of private medical insurance. (o)

Responses conflicted between serological tests being conducted at both public and private laboratories vs. not being conducted in the country.

Private Sector Discussion Note: COVID-19 Testing

Enabling the private health sector in the national response to COVID-19: Six Current Policy Challenges

Xpert MTB/RIF for tuberculosis testing: access and price in highly privatised health markets

New TB Tools Need to be Affordable in the Private Sector: The Case Study of Xpert MTB/RIF

Coronavirus Disease (COVID-19) Situation Report 145

World Health Organization. ENGAGING THE PRIVATE HEALTH DELIVERY SECTOR IN THE RESPONSE TO THE COVID-19: A PLAN OF ACTION -Interim Guidance

Initiative for Promoting Affordable and Quality Tuberculosis Tests (IPAQT): a market-shaping intervention in India